Navigation Links
Enteris BioPharma and Nordic BioScience's KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris' Proprietary Oral Drug Delivery and Manufacturing Platform
Date:9/30/2013

BOONTON, N.J., Sept. 30, 2013 /PRNewswire/ -- Enteris BioPharma, Inc., an industry leader in innovative oral dosage formulations, and KeyBioScience, a wholly-owned subsidiary of Nordic Bioscience, today announced a strategic licensing agreement for Enteris' oral drug delivery and recombinant manufacturing technologies to advance the development of KeyBioScience's recently acquired family of proprietary metabolic peptides for various indications, including the treatment of Type 2 diabetes, obesity and other inflammatory conditions with high unmet medical and socioeconomic needs. 

The licensing agreement with KeyBioScience marks the first significant revenue-generating partnership for Enteris since its inception in April 2013, and is representative of the company's broader "Feasibility-to-Licensing" strategy involving Peptelligence™, its peptide and small molecule oral drug delivery platform.  For KeyBioScience, the licensing agreement signals its transition to a clinical stage company following its formation by Nordic Bioscience. 

Under the terms of the agreement, Enteris will license to KeyBioScience its oral drug delivery and recombinant manufacturing technologies, as well as become the exclusive provider of pre-clinical and clinical trial API and solid dosage form finished product and will receive both fee-for-service revenues and royalties based on net sales of the developed products. 

Brian Zietsman, President and CFO of Enteris BioPharma, commented, "I cannot overemphasize the significance of this licensing agreement for Enteris and the excitement we share with Nordic Bioscience and its wholly-owned subsidiary KeyBioScience, especially given the tremendous potential therapeutic benefit and multi-billion dollar commercial potential of the compounds under development.  Importantly, for Enteris, this licensing agreement showcases our unique ability to partner with global pharmaceutical companies to develop and progress orally delivered peptide and small molecule drugs utilizing our Peptelligence™ platform.  Looking ahead, we are focused on expanding our portfolio of 'feasibility-to-licensing' agreements with both established and emerging biopharmaceutical companies that recognize the market opportunity afforded by formulating peptides and small molecules for oral drug delivery."

Dr. Morten Asser Karsdal, Professor and CEO of KeyBioScience, remarked, "Advancing the licensed peptides to the clinic is the first step in what we believe will ultimately become a new paradigm for peptide-based therapeutics and the treatment of metabolic disease.  Our ability to both apply and leverage Enteris' Peptelligence™ platform will be critical to our success as we progress into advanced-stage clinical trials and potential commercialization."

Peptelligence™ is a clinically proven formulation technology that enables the oral delivery of BCS class II, III and IV peptide and small molecule compounds in a proprietary enteric-coated tablet formulation.  Peptelligence™ has demonstrated a unique track record of clinical success across a range of compounds and therapeutic indications, including a positive outcome pivotal Phase 3 trial.

About Nordic Bioscience
Nordic Bioscience discovers and develops innovative medical treatments to help millions of people around the world suffering from serious, chronic, degenerative diseases such as osteoporosis and osteoarthritis, as well as metabolic disorders such as Type 2 diabetes.  Since its incorporation in 1989, Nordic Bioscience has strived to revolutionize the in vitro diagnostics field, allowing the company to discover and design innovative drug development programs, in part through highly focused drug repositioning by serological measurements. The in-house developed biomarker platform, a unique measure of protein fingerprints, positions Nordic Bioscience as the leading scientific company within biomarker development.

About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. 
Peptelligence™ has demonstrated a track record of clinical success across a range of compounds and therapeutic indications and has also been the subject of numerous feasibility studies and active development programs, several of which are in advanced stages of clinical development. For more information on Enteris BioPharma and Peptelligence™, please visit http://www.EnterisBioPharma.com.

For Enteris BioPharma:          

Media Contacts:

Arlyn Peguero

973.453.3530

Jason Rando / Claire Sojda

Tiberend Strategic Advisors, Inc.

212.827.0020

jrando@tiberend.com

csojda@tiberend.com


'/>"/>
SOURCE Enteris BioPharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Enteris BioPharma Initiates Business and Development Activities Targeting Oral Delivery of Peptides and Small Molecule Therapeutics
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
3. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
4. CeNeRx BioPharma Completes $4.85 Million Financing
5. PDL BioPharma Completes Regular Quarterly Dividend Payment
6. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
9. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
10. Sigma-Aldrich to Acquire BioReliance; Extending Its Reach into Biopharmaceutical Testing and Services
11. Galien Foundation Announces 2012 Awards Program For Best Biopharmaceutical Products and Best Medical Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... On Thursday, February 11, 2-1-1 San ... health and disaster services, and the Community Information ... care coordination and service delivery for the community to ... to better connect service providers to the information they ... Diego has handled more than 2.5 million ...
(Date:2/4/2016)... San Francisco, CA (PRWEB) , ... February 04, ... ... future of enterprise talent development and compliance training, today announced an interactive ... on Morf Playbook™. The RAPS (Regulatory Affairs Professional Society) accredited interactive course ...
(Date:2/4/2016)... ... February 04, 2016 , ... Shimadzu Scientific ... LC-MS, host live demos and poster sessions, and present on the analysis of ... takes place March 6 to 10 at the Georgia World Congress Center in ...
(Date:2/4/2016)... Feb. 4, 2016  CytoSorbents Corporation (NASDAQ: ... its flagship CytoSorb® blood filter to treat deadly ... the world, announced that CEO Dr. Phillip ... Source Capital Group,s 2016 Disruptive Growth & Healthcare ... company.  Conference Presentation Details: ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/11/2016)... 2016 Synaptics Incorporated (NASDAQ: SYNA ), ... that its ClearPad ® TouchView ™ 4300 ... separate categories in the 8 th Annual Mobile ... Breakthrough. The Synaptics ® TDDI solution enables faster ... thinner devices, brighter displays and borderless designs. ...
(Date:1/7/2016)... Jan. 7, 2016 Various factors have ... products such as biologics and biosimilars. Some of ... healthcare expenditure, growing demand for cost-effective alternatives, growing ... Biosimilars are similar versions of their corresponding patented ... their quality, safety, and efficacy. The global biosimilars ...
Breaking Biology News(10 mins):